Company Encyclopedia
View More
name
Summit Therapeutics
SMMT.US
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
1.945 T
SMMT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)

    Citi analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics with a price target of $131.90, while shares closed at $17.25. The analyst has a 4.7% average return and a 39.51% success rate. The consensus rating for Summit Therapeutics is Moderate Buy with a $39.09 average price target.

    Tip Ranks·
    US
    SMMT
    -2.84%
    Tip Ranks·
    US
    SMMT
    -2.84%

    Insider Buying After Losses Could Be a Game Changer for Summit Therapeutics (SMMT)

    Summit Therapeutics reported a wider EBITDA loss and a further drop in EPS for Q3 2025. Despite this, several company directors purchased millions of dollars’ worth of shares, indicating internal optimism. The upcoming Biologics License Application for ivonescimab is a critical short-term catalyst. However, heavy losses, a significant share price drop, and reduced analyst confidence highlight the need for cautious optimism. Fair value estimates for the stock vary widely, reflecting differing opinions on its potential.

    Simplywall·
    US
    SMMT
    -2.84%
    Simplywall·
    US
    SMMT
    -2.84%

    Summit Therapeutics (SMMT) Gets a Buy from UBS

    UBS analyst David Dai has maintained a Buy rating on Summit Therapeutics (SMMT) with a price target of $33.00, while the shares closed at $18.30. The overall analyst consensus for Summit Therapeutics is a Moderate Buy, with an average price target of $30.82. Dai has an average return of -5.6% and a success rate of 44.44% on his stock recommendations.

    Tip Ranks·
    US
    SMMT
    -2.84%
    Tip Ranks·
    US
    SMMT
    -2.84%

    Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements

    TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Summit Therapeutics (SMMT) stock, citing a positive outlook following the company's recent earnings report. The rating reflects confidence in the company's strategic focus on advancing its clinical pipeline, particularly with ongoing Phase III trials and the upcoming HARMONi-GI3 trial. Van Buren, who covers the Healthcare sector, has an average return of 8.2% and a 50.52% success rate on recommended stocks.

    Tip Ranks·
    US
    SMMT
    -2.84%
    Tip Ranks·
    US
    SMMT
    -2.84%

    Clear Street Remains a Buy on Summit Therapeutics (SMMT)

    Clear Street analyst William Maughan has maintained a Buy rating on Summit Therapeutics (SMMT) with a price target of $32.00. Maughan, who specializes in the Healthcare sector, has an average return of 19.8% and a success rate of 46.81% on his stock recommendations. The analyst consensus for Summit Therapeutics is a Moderate Buy, with a price target consensus of $30.55.

    Tip Ranks·
    US
    SMMT
    -2.84%
    Tip Ranks·
    US
    SMMT
    -2.84%
    Posts
    View More

    $Summit Therapeutics(SMMT.US) is so strong... healthcare stocks

    © 2025 Longbridge｜Disclaimer